Dai­ichi Sankyo gets US patent of­fice to restart re­view of Seagen patent

Dai­ichi Sankyo is go­ing back af­ter Seagen in the lat­est bout of patent in­fringe­ment ac­cu­sa­tions.

The Japan­ese phar­ma an­nounced Fri­day that the US Patent and Trade­mark Of­fice (PTO) has agreed to the com­pa­ny’s re­quest to restart a post-grant re­view of a Seagen patent.

A post-grant re­view (PGR) is when the patent of­fice’s board — called the Patent Tri­al and Ap­peal Board — ex­am­ines at least one claim from an ex­ist­ing patent in a bid to de­ter­mine if that claim is ca­pa­ble of be­ing patent­ed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER